Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Complicated Skin and Skin Structure Infections Clear all
Completed Phase 2 Interventional Results available

Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections

NCT00633152
View directory record Official record
Conditions
Bacterial Infection
Interventions
ceftaroline, linezolid, Aztreonam
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
13
States / cities
Buena Park, California • Long Beach, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Jul 21, 2026, 6:08 PM EDT
Completed No phase listed Observational

Telavancin Observational Use Registry (TOUR)

NCT02288234
View directory record Official record
Conditions
Hospital Acquired Bacterial Pneumonia, Complicated Skin and Skin Structure Infections, Ventilator Associated Bacterial Pneumonia, Gram Positive Infection
Interventions
Vibativ
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
1,063 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 2 Interventional Results available

Study the Efficacy and Safety of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

NCT03716024
View directory record Official record
Conditions
Infectious Skin Disease, Bacterial Skin Disease
Interventions
PTK 0796, Linezolid
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
11
States / cities
Anaheim, California • Buena Park, California • Chula Vista, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2020 · Synced Jul 21, 2026, 6:08 PM EDT
Terminated Phase 4 Interventional Results available

Study Comparing Cubicin With Vancomycin in Treatment of Participants With Complicated Skin and Skin Structure Infections in a Home Infusion Setting

NCT01175707
View directory record Official record
Conditions
Complicated Skin or Skin Structure Infection
Interventions
Daptomycin, Vancomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Livonia, Michigan • Roseville, Minnesota • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2018 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections

NCT01549613
View directory record Official record
Conditions
Cellulitis, Skin Infections
Interventions
Daptomycin, Vancomycin
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of JNJ-32729463 for Treating Complicated Skin and Skin Structure Infections Compared to Linezolid (Zyvox)

NCT01128530
View directory record Official record
Conditions
Complicated Skin and Skin Structure Infections
Interventions
JNJ-32729463, linezolid, JNJ-32729463 placebo, linezolid placebo
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
27
States / cities
Anaheim, California • Buena Park, California • Chula Vista, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

NCT00091819
View directory record Official record
Conditions
Staphylococcal Skin Infection
Interventions
Telavancin, Vancomycin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
National City, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections

NCT00761215
View directory record Official record
Conditions
Skin Diseases, Infectious, Skin Diseases, Bacterial
Interventions
TR-701 200 mg, TR-701 300 mg, TR-701 400 mg
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
Dothan, Alabama • Chula Vista, California • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

NCT00424190
View directory record Official record
Conditions
Bacterial Infections
Interventions
IV Vancomycin plus IV Aztreonam, Ceftaroline
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
15
States / cities
Dothan, Alabama • Long Beach, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus

NCT01593761
View directory record Official record
Conditions
Skin Infection
Interventions
CG400549
Drug
Lead sponsor
CrystalGenomics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
La Mesa, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Not applicable Interventional

MicroMatrix® Flex in Tunneling Wounds

NCT06629506
View directory record Official record
Conditions
Pressure Injury, Venous Ulcer, Necrotizing Soft Tissue Infection, Diabetic Ulcers, Draining Wound
Interventions
MicroMatrix® Flex, MicroMatrix® UBM Particulate, Cytal® Wound Matrix 2-Layer
Device
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
22 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 4 Interventional Results available

Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA

NCT01419184
View directory record Official record
Conditions
Staphylococcal Skin Infections
Interventions
Daptomycin, Vancomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
25
States / cities
Mobile, Alabama • Chula Vista, California • Escondido, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 4 Interventional Results available

Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)

NCT00087490
View directory record Official record
Conditions
Skin/Soft Tissue Infections, Methicillin Resistant Staphylococcus Aureus (MRSA)
Interventions
linezolid, vancomycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,077 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
76
States / cities
Montgomery, Alabama • Tucson, Arizona • Los Angeles, California + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections

NCT00711802
View directory record Official record
Conditions
Skin Diseases, Infectious
Interventions
Daptomycin, Standard of Care (SOC)
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
1 Year to 17 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
22
States / cities
Birmingham, Alabama • Oakland, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 2 Interventional

Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections

NCT00426933
View directory record Official record
Conditions
Soft Tissue Infections
Interventions
Daptomycin, Vancomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Idaho Falls, Idaho
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 2 Interventional

Safety, Potential Efficacy, and Pharmacokinetics of PZ-601 in the Treatment of Complicated Skin and Skin Structure Infection

NCT00671580
View directory record Official record
Conditions
Skin Infections
Interventions
PZ-601, Standard of Care
Drug
Lead sponsor
Protez Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
15
States / cities
Chula Vista, California • Fountain Valley, California • Long Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2009 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections

NCT01499277
View directory record Official record
Conditions
Complicated Skin and Soft Tissue Infection
Interventions
Ceftaroline fosamil, Vancomycin, Aztreonam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
10
States / cities
Chula Vista, California • Orlando, Florida • West Palm Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Jul 21, 2026, 6:08 PM EDT
Terminated Phase 4 Interventional

Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure Infections

NCT00102947
View directory record Official record
Conditions
Soft Tissue Infections
Interventions
daptomycin (up to 14 days)
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
12
States / cities
Torrance, California • Tampa, Florida • Augusta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2016 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

NCT00107978
View directory record Official record
Conditions
Staphylococcal Skin Infection
Interventions
Telavancin, Vancomycin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

NCT00423657
View directory record Official record
Conditions
Bacterial Infections
Interventions
ceftaroline, vancomycin plus aztreonam, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
17
States / cities
Buena Park, California • Hawaiian Gardens, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Jul 21, 2026, 6:08 PM EDT
Terminated Phase 4 Interventional Results available

Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment

NCT01104662
View directory record Official record
Conditions
Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia, Renal Impairment
Interventions
Vancomycin, Daptomycin, Semi-Synthetic Penicillin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Azusa, California • Los Angeles, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

NCT00061633
View directory record Official record
Conditions
Infections, Gram-Positive Bacterial, Abscess, Burns, Cellulitis, Ulcer, Wound Infections
Interventions
Telavancin, Vancomycin or antistaphylococcal penicillin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of a Fluoroquinolone to Treat Complicated Skin Infections

NCT00719810
View directory record Official record
Conditions
Skin Structure Infections, Bacterial Skin Diseases, Staphylococcal Skin Infections
Interventions
delafloxacin, tigecycline
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
13
States / cities
Anaheim, California • Hawaiian Gardens, California • Oceanside, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2014 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 2 Interventional

A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections

NCT00303589
View directory record Official record
Conditions
Soft Tissue Infections
Interventions
Standard care, beta-lactam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
8
States / cities
Birmingham, Alabama • Mobile, Alabama • Melbourne, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 21, 2026, 6:08 PM EDT